# Atavistik Bio

> Atavistik Bio is a Cambridge, Massachusetts clinical-stage biotechnology company that discovers precision allosteric small-molecule medicines. Its proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, paired with an AI-enabled discovery engine, uses natural metabolites as bait to reveal hidden allosteric pockets on disease-driving proteins that conventional drug discovery cannot reach. The company is advancing an oral AKT1-selective inhibitor for hereditary hemorrhagic telangiectasia (HHT) and a JAK2 V617F mutant-selective program for myeloproliferative neoplasms (MPNs).

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Jared Rutter (Scientific Co-Founder (Professor of Biochemistry, University of Utah)), Ralph DeBerardinis (Scientific Co-Founder (Professor, UT Southwestern Medical Center)), Marion Dorsch (Co-Founder, President & Chief Scientific Officer)
- **Team size:** ~37 employees
- **Products:** AMPS (Atavistik Metabolite-Protein Screening) Platform, AI-Enabled Discovery Engine, ATV-1601, JAK2 V617F Program
- **Notable:** Raised approximately $340M in total funding since 2021., Closed a $120M Series B in December 2025 led by Nextech Invest and The Column Group with Regeneron Ventures joining., Foundational AMPS/MIDAS technology published in Science (2023) by co-founder Jared Rutter.

## Products & services

- **AMPS (Atavistik Metabolite-Protein Screening) Platform** — A discovery engine that uses natural metabolites as bait to systematically reveal hidden allosteric binding pockets on proteins and functional sites on RNA. Industrialized from the MIDAS technique developed in Jared Rutter's lab and published in Science.
- **AI-Enabled Discovery Engine** — AI and structure-based design layered onto AMPS data to rapidly advance validated allosteric sites from discovery into small-molecule development.
- **ATV-1601** — Oral allosteric AKT1-selective inhibitor. Lead program for hereditary hemorrhagic telangiectasia (HHT); received FDA IND clearance and Fast Track Designation. Also explored as a selective AKT1 E17K inhibitor in advanced solid tumors and breast cancer.
- **JAK2 V617F Program** — Mutant-selective allosteric inhibitor targeting the JAK2 V617F driver mutation in myeloproliferative neoplasms (MPNs).

## Achievements

- Raised approximately $340M in total funding since 2021.
- Closed a $120M Series B in December 2025 led by Nextech Invest and The Column Group with Regeneron Ventures joining.
- Foundational AMPS/MIDAS technology published in Science (2023) by co-founder Jared Rutter.
- ATV-1601 received FDA IND clearance and Fast Track Designation for HHT.
- Advanced two distinct clinical-stage programs (AKT1 for HHT; JAK2 V617F for MPNs) from a single platform.

## Latest updates

- **2026-06** — ATV-1601 reported with FDA IND clearance and Fast Track Designation for hereditary hemorrhagic telangiectasia (HHT).
- **2026-03** — Raised an additional ~$40M (Series B extension) to advance its rare bleeding-disorder (HHT) program; RA Capital added as investor.
- **2025-12** — Closed $120M Series B to advance AKT1-selective (HHT) and JAK2 V617F-selective (MPNs) programs through clinical proof of concept.
- **2023-03** — Published foundational AMPS/MIDAS technology in Science, authored by co-founder Jared Rutter.

## Links

- Website: https://atavistikbio.com
- LinkedIn: https://www.linkedin.com/company/atavistik-bio
- Twitter/X: https://twitter.com/AtavistikBio

---

Profile page: https://yespress.io/atavistik-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-22